# QUILT-3.078 (NCT06061809)

> N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

No report yet. It can be ordered.

- Indication: recurrent or progressive glioblastoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06061809
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ImmunityBio, Inc.
- Conditions: Glioblastoma
- Interventions: Bevacizumab; PD-L1 t-haNK; N-803; Tumor Treating Fields (TTFields, 200 kHz)
- Enrollment: 34
- Primary outcome: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
- Primary outcome: Incidence of clinically significant changes in comprehensive metabolic panel (CMP)
- Primary outcome: Incidence of clinically significant changes in Hematology blood panel.
- Primary outcome: Incidence of clinically significant changes in Urinalysis.
- Primary outcome: 12-lead Electrocardiogram (ECG)
- Primary outcome: Incidence of clinically significant changes in Temperature
- Primary outcome: Incidence of clinically significant changes in Heart Rate
- Primary outcome: Incidence of clinically significant changes in Respiratory Rate
- Primary outcome: Incidence of clinically significant changes in Blood Pressure
- Primary outcome: Incidence of clinically significant changes in Oxygen Saturation
- Primary outcome: Neurological assessment to grade Immune effector cell-associated neurotoxicity syndrome (ICANS)
- Primary outcome: Safety assessed by Cytokine Levels

## Indexed commentary on QUILT-3.078 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 posts on X
- 1 YouTube video

## Order

Focused first edition, $750. Buy the first edition with create_order on https://mcp.erudio.com/mcp (product "first_edition", report "NCT06061809", the buyer's work email and organization), or POST https://www.erudio.com/api/orders with the same fields. It returns a Stripe checkout_url for your person to pay by card; a first edition has no agent-wallet payment. The person can also order on https://www.erudio.com/trials/quilt-3-078-nct06061809. We build the first edition within 24 hours of payment and email it to you once it passes our checks and review. If your report can't be delivered, we'll contact you and refund it in full.

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06061809", "email": "<work email>"}; the inbox owner confirms by the emailed link.
